Accord Healthcare, Inc.

Accord Healthcare, Inc. is the United States subsidiary of Intas Pharmaceuticals, a global pharmaceutical company headquartered in Ahmedabad, India. The U.S. operations, based in Durham, North Carolina, were established in 2009. Accord Healthcare is a privately held entity within the Intas Group. As the commercial arm of Intas in the U.S., the company is a significant provider of generic pharmaceuticals.

Accord Healthcare develops, manufactures, and markets a broad portfolio of generic pharmaceuticals, biosimilars, and specialty medicines. The company's product lines span a full range of dosage forms, including oral solids, topicals, liquids, and complex injectables. It has a particular focus on oncology, holding a significant volume share of major chemotherapy injectable molecules. Other key therapeutic areas include cardiology, neurology, psychiatry, and pain management. The company operates with a vertically integrated model, leveraging research and development and manufacturing facilities, including three FDA-approved plants in India.

As an operating company focused on bringing generic drugs to market, Accord Healthcare's patent litigation posture is that of a defendant in suits brought by brand-name pharmaceutical companies. The single tracked case is consistent with this profile, showing Accord as a defendant, not a plaintiff. This type of litigation is a standard part of the business for generic manufacturers under the Hatch-Waxman Act.

The company's one tracked case is Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al., filed in 2022 in the U.S. District Court for the District of Delaware. The lawsuit arose from Accord's submission of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of Veloxis's drug, ENVARSUS XR® (tacrolimus), an immunosuppressant used for transplant patients. This action for patent infringement is a typical response by a brand-name drug holder when a generic competitor challenges its patents to bring a lower-cost alternative to market.